Richard S, Beigelman C, Gerber S, Van Effenterre R, Gaudric A, Sahel M, Binaghi M, De Kersaint-Gilly A, Houtteville J P, Brunon J P
Laboratoire de Neurohistologie EPHE, La Salpêtrière, Hôpital Lariboisière, Paris.
Neurochirurgie. 1994;40(3):145-54.
Hemangioblastoma may arise in isolation ("sporadic" cases) or as a major manifestation of von Hippel-Lindau (VHL) disease, an autosomal dominant disorder with a prevalence of at least 1/36,000. In addition of central nervous system hemangioblastomas (cerebellum, spinal cord and retina), affected patients may develop renal cysts or carcinomas, pheochromocytomas and pancreatic cysts. A multidisciplinary group including neurosurgeons, geneticists, pathologists and clinicians from all involved specialities has been organized to develop a national registration of all hemangioblastoma and VHL patients. The findings of a preliminary 10-year study (1983-1993) conducted in France are presented. Two hundred thirteen cases of hemangioblastoma were reviewed for their location and genetic features. The majority (77%) of the tumors were located in the cerebellum whereas 23% were located inside the spinal canal. By thorough clinical examination of the patients and systematic genetic inquiry of their family background, it was found that 34.3% of the total (58.7% before age 30) were afflicted with VHL disease. Spinal hemangioblastomas were more often related to VHL disease than infra-tentorial locations (50% versus 36.6%). In addition, mean age at diagnosis in VHL disease was significantly younger than in sporadic cases (33.5 +/- 10 versus 43.6 +/- 15 years). Recent progress in VHL molecular genetics led to the identification of the mutated gene to the distal part of the short arm of chromosome 3 (3p25-3p26), paving the way to presymptomatic diagnosis and, hopefully, to elucidation of pathogenesis, which may offer a further glimpse into tumorigenesis in general. Because of the usually early adulthood onset, accurate presymptomatic diagnosis of affected members would be of great benefit to VHL families. However, the fact that very few mutations in the VHL gene are identified precludes molecular diagnosis of "sporadic" hemangioblastomas. In summary, this study reveals that VHL-related hemangioblastoma is a more common clinical problem that it was previously reported. Thus, all patients with an apparently isolated central nervous system hemangioblastoma should be investigated for evidence of VHL disease.
血管母细胞瘤可单独出现(“散发”病例),也可作为冯·希佩尔 - 林道(VHL)病的主要表现形式出现,VHL病是一种常染色体显性疾病,患病率至少为1/36,000。除了中枢神经系统血管母细胞瘤(小脑、脊髓和视网膜)外,患病患者还可能出现肾囊肿或癌、嗜铬细胞瘤和胰腺囊肿。一个由神经外科医生、遗传学家、病理学家以及所有相关专业的临床医生组成的多学科团队已组建起来,以对所有血管母细胞瘤和VHL病患者进行全国性登记。本文介绍了在法国进行的一项为期10年的初步研究(1983 - 1993年)的结果。对213例血管母细胞瘤病例的位置和遗传特征进行了回顾。大多数肿瘤(77%)位于小脑,而23%位于椎管内。通过对患者进行全面的临床检查以及对其家族背景进行系统的遗传调查,发现总共34.3%的患者(30岁之前为58.7%)患有VHL病。脊髓血管母细胞瘤比幕下部位的血管母细胞瘤更常与VHL病相关(50%对36.6%)。此外,VHL病患者的平均诊断年龄明显低于散发病例(33.5±10岁对43.6±15岁)。VHL分子遗传学的最新进展导致在3号染色体短臂远端(3p25 - 3p26)鉴定出突变基因,为症状前诊断铺平了道路,并有望阐明发病机制,这可能会让人们对肿瘤发生的总体情况有更深入的了解。由于通常在成年早期发病,对患病成员进行准确的症状前诊断对VHL家族将大有裨益。然而,VHL基因中鉴定出的突变极少,这使得无法对“散发”血管母细胞瘤进行分子诊断。总之,这项研究表明,与VHL相关的血管母细胞瘤是一个比之前报道更为常见的临床问题。因此,所有明显患有孤立性中枢神经系统血管母细胞瘤的患者都应接受检查,以寻找VHL病的证据。